Results 61 to 70 of about 11,390 (145)

Adding capivasertib to fulvestrant in patients with hormone receptor-positive advanced breast cancer: a cost-effectiveness analysis

Frontiers in Pharmacology
ObjectiveCapivasertib, a novel pan-AKT inhibitor, shows significant antitumor activity against hormone receptor-positive advanced breast cancer. However, its cost-effectiveness of this treatment remains uncertain.
Yitian Lang, Qingqing Chai, Yan Lin, Bin Wu, Xiaoyan Liu   +4 more
doaj   +1 more source

Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer

Case Reports in Oncology, 2010
We report a case of long-term (9 years) response to 4th-line endocrine treatment with fulvestrant given for advanced breast cancer after no or poor response to prior endocrine therapies.
H. Hawle, D. Hess, A. Mueller, B. Thuerlimann   +3 more
doaj   +1 more source

Application of fluorocarbon nanoparticles of 131I-fulvestrant as a targeted radiation drug for endocrine therapy on human breast cancer

Journal of Nanobiotechnology
Background Breast cancer is the most prevalent malignant tumor among women, with hormone receptor-positive cases constituting 70%. Fulvestrant, an antagonist for these receptors, is utilized for advanced metastatic hormone receptor-positive breast cancer.
Li Zhi, Chen Cheng, Luo Jing, Peng Zhi-Ping, Yang Lu, Tian Yan, Wang Zhi-Gang, Yin Guo-Bing   +7 more
doaj   +1 more source

Insulin-like growth factor-binding protein-3 is induced by tamoxifen and fulvestrant and modulates fulvestrant response in breast cancer cells

Frontiers in Oncology
IntroductionInsulin-like growth factor binding protein-3 (IGFBP-3) exerts varying effects on estrogen receptor alpha (ERα)-positive and triple-negative breast cancer (TNBC) cells. In ERα-positive cells, IGFBP-3 is antiproliferative and proapoptotic.
Keenan L. Flynn, Yan Zheng, Janel Y. Sowers, Nefretiri J. T. Masangya, Kevin D. Houston   +4 more
doaj   +1 more source

Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review

Frontiers in Oncology, 2019
Introduction: Hormonal therapy in endometrial cancer (EC) is used for patients who wish to preserve fertility and for patients with advanced or recurrent disease in a palliative setting.
Willem Jan van Weelden, Leon F. A. G. Massuger, ENITEC, Johanna M. A. Pijnenborg, Andrea Romano   +4 more
doaj   +1 more source

Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1

Pharmacogenomics and Personalized Medicine, 2011
Vineetha Koroth Edavana1, Xinfeng Yu1, Ishwori B Dhakal1, Suzanne Williams1, Baitang Ning2, Ian T Cook3, David Caldwell1, Charles N Falany3, Susan Kadlubar11Division of Medical Genetics, College of Medicine, University of Arkansas for Medical Sciences ...
Edavana VK, Yu X, Dhakal IB, Williams S, Ning B, Cook IT, Caldwell D, Falany CN, Kadlubar S   +8 more
doaj  

Fulvestrant [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data

Cancer Management and Research, 2022
Hikmat Abdel-Razeq,1,2 Baha’ Sharaf,1 Rama AlMasri,3 Rashid Abdel-Razeq,1 Faris Tamimi,1 Omar Khader,1 Osama Salama,1 Mahmoud Abunasser,1 Sarah Edaily,1 Hazem Abdulelah1 1Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan ...
Abdel-Razeq H, Sharaf B, AlMasri R, Abdel-Razeq R, Tamimi F, Khader O, Salama O, Abunasser M, Edaily S, Abdulelah H   +9 more
doaj  

Capivasertib/Fulvestrant in patients with HR+, HER2-low or HER2-negative locally advanced or metastatic breast cancer

Therapeutic Advances in Medical Oncology
The landscape of breast cancer treatment continues to evolve. Survival rates have improved due to advancements in treatments such as endocrine therapy, cyclin-dependent kinase 4/6 inhibitors and targeted therapies.
Karam Aboud, Magda Meissner, Rob Jones
doaj   +1 more source

Identification of fulvestrant analogues for estrogen receptor alpha binding in breast cancer using molecular docking and molecular dynamics simulation

Discover Chemistry
Breast cancer remains a major global health challenge, with approximately 80% of cases classified as estrogen receptor-positive (ER+). Fulvestrant, a steroidal antiestrogen and selective estrogen receptor degrader (SERD), is widely used in ER+ breast ...
Atharva Balpande, Anushka Dashputra, Nikhil Khanwani, Yashasvi Therkar, Aryan Wasewar, Ganesh C. Patil, C. Ravikumar   +6 more
doaj   +1 more source